

What is claimed is

1. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein neither interferon nor ribavirin are administered to said patient, and said treatment lasts for 12 weeks, and wherein said at least two DAAs comprise:
Compound 1 having formula of




or a pharmaceutically acceptable salt thereof, and Compound 4 having formula of



or a pharmaceutically acceptable salt thereof, wherein Compound 1 or the salt thereof is to be co-administered with ritonavir.


2. The use of claim 1, wherein said patient is a treatment-naïve patient.

3. The use of claim 1, wherein said at least two DAAs further comprise compound 2 having formula of



or a pharmaceutically acceptable salt thereof.

4. The use of claim 2, wherein said at least two DAAs further comprise compound 2 having formula of



or a pharmaceutically acceptable salt thereof.

5. The use of claim 1, wherein said patient is infected with HCV genotype 1a.

6. The use of claim 2, wherein said patient is infected with HCV genotype 1a.

7. The use of claim 3, wherein said patient is infected with HCV genotype 1a.

8. The use of claim 4, wherein said patient is infected with HCV genotype 1a.

9. Use of at least two direct acting antiviral agents (DAAs)) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein neither interferon nor ribavirin are administered to said patient, wherein said at least two DAAs comprise PSI-7977 and TMC-435, and wherein said treatment lasts for 12 weeks.

10. The use of claim 9, wherein said patient is a treatment-naïve patient.

11. The use of claim 9, wherein said patient is infected with HCV genotype 1a.

12. The use of claim 10, wherein said patient is infected with HCV genotype 1a.

13. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein

neither interferon nor ribavirin are administered to said patient, wherein said at least two DAAs comprise PSI-7977 and GS-5885, and wherein said treatment as for 12 weeks.


14. The use of claim 13, wherein said patient is a treatment-naïve patient.

15. The use of claim 13, wherein said patient is infected with HCV genotype 1a.


16. The use of claim 14, wherein said patient is infected with HCV genotype 1a.

17. The use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV treatment-naïve patient infected with HCV genotype 1, wherein neither interferon nor ribavirin are administered to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise

Compound 1




Compound 2



and

Compound 4



and wherein Compound 1 is to be co-administered with ritonavir.

18. The use of claim 17, wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition to be administered once daily, and Compound 2 is to be administered twice daily.

19 The use of claim 17, wherein Compound 1 is to be administered 150 mg once daily together with 100 mg of ritonavir once daily and Compound 4 is to be administered 25mg once daily, Compound 2 is to be administered 400mg twice daily.

20. The use of claim 17, wherein said patient is infected with HCV genotype 1a.

21. The use of claim 18, wherein said patient is infected with HCV genotype 1a.

22. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV treatment-naïve patient infected with HCV genotype 1, wherein neither interferon nor ribavirin are administered to said patient, and said treatment lasts for 8 weeks, and wherein said at least two DAAs comprise PSI-7977 and GS-5885.

23. The use of claim 22, wherein said two DAAs are to be administered once daily.

24. The use of claim 22, wherein said two DAAs are to be co-formulated in a single composition to be administered once daily.

25. The use of claim 22, wherein PSI-7977 is to be administered 400 mg once daily and GS-5885 is to be administered 90 mg once daily.

26. The use of claim 22, wherein said patient is infected with HCV genotype 1a.

27. The use of claim 23, wherein said patient is infected with HCV genotype 1a.

28. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV treatment-naïve patient infected with HCV genotype 1, wherein neither interferon nor ribavirin are administered to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, or said at least two DAAs comprise PSI-7977 and GS-5885.

29. The use of claim 28, wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, and Compound 1 is to be co-administered with ritonavir.

30. The use of claim 29, wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition to be administered once daily, and Compound 2 is to be administered twice daily.

31. The use of claim 29, wherein Compound 1 is to be administered 150 mg once daily together with 100 mg ritonavir once daily, Compound 4 is to be administered 25mg once daily, and Compound 2 is to be administered 400mg twice daily.

32. The use of claim 29, wherein said patient is infected with HCV genotype 1a.

33. The use of claim 28, wherein said at least two DAAs comprise PSI-7977 and GS-5885.


34. The use of claim 33, wherein said at least two DAAs are to be administered once daily.

35. The use of claim 33, wherein said two DAAs are co-formulated in a single composition and are to be administered once daily.

36. The use of claim 33, wherein said patient is infected with HCV genotype 1a.

37. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in an HCV patient, wherein said treatment lasts for 8 weeks, wherein neither interferon nor ribavirin are administered to said patient and said at least two DAAs comprise PSI-7977 and an HCV NS5A inhibitor, and wherein said patient is a treatment-naïve patient infected with HCV genotype 1.

38. The use of claim 37, wherein said HCV NS5A inhibitor is Compound 4




39. The use of claim 37, wherein said PSI-7977 is to be administered 400 mg once daily.


40. The use of claim 37, wherein said PSI-7977 and said HCV NS5A inhibitor are co-formulated in a single composition to be administered once daily.

41. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treatment of HCV in a patient infected with HCV genotype 1, wherein said treatment lasts for 6 or 7 weeks, wherein neither interferon nor ribavirin are administered to said patient, and said at least two DAAs comprise PSI-7977, an HCV NS5A inhibitor and another DAA.

42. The use of claim 41, wherein said another DAA is Compound 1



and said HCV NS5A inhibitor is Compound 4



43. The use of claim 41, wherein said PSI-7977 is to be administered at a dose of 400 mg once daily.

44. The use of claim 41, wherein said another DAA is an HCV protease inhibitor.

45. The use of claim 41, wherein said another DAA is an HCV polymerase inhibitor.

46. The use of claim 41, wherein said patient is a treatment naïve patient.

47. The use of claim 41, wherein said patient is an interferon non-responder.

WHAT IS CLAIMED IS:

1. A combination comprising PSI-7977 and GS-5885 for the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

2. The combination of claim 1, wherein the treatment lasts for 8 weeks.

3. The combination of claim 1, wherein the treatment lasts for 12 weeks.

4. The combination of claims 1, 2, or 3, wherein the patient is treatment-naive.

5. The combination of claims 1, 2, or 3, wherein the HCV is genotype 1a.

6. The combination of claims 1, 2, or 3, wherein the patient is treatment-naive, and said PSI-7977 and GS-5885 are adapted for administration once daily.

7. The combination of claims 1, 2, or 3, wherein the patient is treatment-naive, and said PSI-7977 and GS-5885 are co-formulated in a single composition and adapted for administration once daily.

8. The combination of claims 1, 2, or 3, wherein the patient is treatment-naive, and 90 mg of GS-5885 is adapted for administration once daily and 400 mg of PSI-7977 is adapted for administration once daily.

9. Use of PSI-7977 and GS-5885 for the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

10. The use of claim 9, wherein the treatment lasts for 8 weeks.

11. The use of claim 9, wherein the treatment lasts for 12 weeks.

12. The use of claims 9, 10, or 11, wherein the patient is treatment-naive.

13. The use of claims 9, 10, or 11, wherein the HCV is genotype 1a.

14. The use of claims 9, 10, or 11, wherein the patient is treatment-naive, and said PSI-7977 and GS-5885 are adapted for administration once daily.

15. The use of claims 9, 10, or 11, wherein the patient is treatment-naive, and said PSI-7977 and GS-5885 are co-formulated in a single composition and adapted for administration once daily.

16. The use of claims 9, 10, or 11, wherein the patient is treatment-naive, and 90 mg of GS-5885 is adapted for administration once daily and 400 mg of PSI-7977 is adapted for administration once daily.

17. A use of a combination comprising PSI-7977 and GS-5885 in the manufacture of a medicament for the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

18. The use according to claim 17, wherein the treatment lasts for 8 weeks.

19. The use according to claim 17, wherein the treatment lasts for 12 weeks.

20. The use of claims 17, 18, or 19, wherein the patient is treatment-naive.

21. The use of claims 17, 18, or 19, wherein the HCV is genotype 1a.

22. The use of claims 17, 18, or 19, wherein the patient is treatment-naive, and said PSI-7977 and GS-5885 are adapted for administration once daily.

23. The use of claims 17, 18, or 19, wherein the patient is treatment-naive, and said PSI-7977 and GS-5885 are co-formulated in a single composition and adapted for administration once daily.

24. The use of claims 17, 18, or 19, wherein the patient is treatment-naive, and 90 mg of GS-5885 is adapted for administration once daily and 400 mg of PSI-7977 is adapted for administration once daily.

25. Use of PSI-7977 in the manufacture of a first medicament and GS-5885 in the manufacture of a second medicament, wherein the first and second medicaments are used in combination for treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

26. The use of claim 25, wherein the treatment lasts for 8 weeks.

27. The use of claim 25, wherein the treatment lasts for 12 weeks.


28. The use of claims 25, 26, or 27, wherein the patient is treatment-naive.

29. The use of claims 25, 26, or 27, wherein the HCV is genotype 1a.


30. The use of claims 25, 26, or 27, wherein the patient is treatment-naive, and said first and second medicaments are adapted for administration once daily.

31. The use of claims 25, 26, or 27, wherein the patient is treatment-naive, and the first medicament comprises 400mg of PSI-7977 and is adapted for administration once daily and the second medicament comprises 90mg of GS-5885 and is adapted for administration once daily.

32. A combination comprising:



Compound 1,
or a pharmaceutically acceptable salt thereof;



Compound 4,
or a pharmaceutically acceptable salt thereof; and

ritonavir for use in the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

33. The combination of claim 32, wherein the treatment lasts for 8 weeks.

34. The combination of claim 32, wherein the treatment lasts for 12 weeks.

35. The combination of claims 32, 33, or 34, wherein 150 mg of Compound 1 is adapted for administration once daily together with 100 mg ritonavir, and 25 mg of Compound 4 is adapted for administration once daily.


36. The combination of claims 32, 33, or 34, wherein the combination is co-formulated with ritonavir in a single composition.

37. The combination of claims 32, 33, or 34, wherein the HCV is genotype 1a.

38. The combination of claims 32, 33, or 34, wherein the HCV is genotype 1b.

39. The combination of claims 32, 33, or 34, wherein the patient is treatment-naive.

40. The combination of claims 32, wherein said combination further comprises



Compound 2,

or a pharmaceutically acceptable salt thereof.

41. The combination of claim 40, wherein the treatment lasts for 8 weeks.

42. The combination of claim 40, wherein the treatment lasts for 12 weeks.

43. The combination of claims 40, 41, or 42, wherein 150 mg of Compound 1 is adapted for administration once daily together with 100 mg ritonavir, 25 mg of Compound 4 is

adapted for administration once daily, and 400 mg of Compound 2 is adapted for administration twice daily.

44. The combination of claims 40, 41, or 42, wherein the pharmaceutically acceptable salt of Compound 2 is the sodium salt.

45. The combination of claims 40, 41, or 42, wherein the HCV is genotype 1a.

46. The combination of claims 40, 41, or 42, wherein the HCV is genotype 1b.

47. The combination of claims 40, 41, or 42, wherein the patient is treatment-naive.

48. Use of Compound 1 and Compound 4, both as defined in claim 32, or a pharmaceutically acceptable salt thereof, and ritonavir in the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

49. The use of claim 48, wherein the treatment lasts for 8 weeks.

50. The use of claim 48, wherein the treatment lasts for 12 weeks.

51. The use of claims 48, 49, or 50, wherein 150 mg of Compound 1 is adapted for administration once daily together with 100 mg ritonavir, and 25 mg of Compound 4 is adapted for administration once daily.

52. The use of claims 48, 49, or 50, wherein the Compound 1 and Compound 4 are co-formulated with the ritonavir in a single composition.

53. The use of claims 48, 49, or 50, wherein the HCV is genotype 1a.

54. The use of claims 48, 49, or 50, wherein the HCV is genotype 1b.

55. The use of claims 48, 49, or 50, wherein the patient is treatment-naive.

56. The use of claim 48, wherein the Compound 1 and Compound 4 are used in combination with Compound 2, as defined in claim 40, or a pharmaceutically acceptable salt thereof.

57. The use of claim 56, wherein the treatment lasts for 8 weeks.

58. The use of claim 56, wherein the treatment lasts for 12 weeks.

59. The use of claims 56, 57, or 58, wherein 150 mg of Compound 1 is adapted for administration once daily together with 100 mg ritonavir, and 25 mg of Compound 4 is adapted for administration once daily, and 400 mg of Compound 2 is adapted for administration twice daily.

60. The use of claims 56, 57, or 58, wherein the pharmaceutically acceptable salt of Compound 2 is the sodium salt.

61. The use of claims 56, 57, or 58, wherein the HCV is genotype 1a.

62. The use of claims 56, 57, or 58, wherein the HCV is genotype 1b.

63. The use of claims 56, 57, or 58, wherein the patient is treatment-naive.

64. Use of a combination comprising Compound 1 and Compound 4, both as defined in claim 32, or a pharmaceutically acceptable salt thereof, and ritonavir, in the manufacture of a medicament for the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

65. The use of claim 64, wherein the treatment lasts for 8 weeks.

66. The use of claim 64, wherein the treatment lasts for 12 weeks.

67. The use of claims 64, 65, or 66, wherein 150 mg of Compound 1 is adapted for administration once daily together with 100 mg ritonavir, and 25 mg of Compound 4 is adapted for administration once daily.

68. The use of claims 64, 65, or 66, wherein the combination is co-formulated with the ritonavir in a single composition.

69. The use of claims 64, 65, or 66, wherein the HCV is genotype 1a.

70. The use of claims 64, 65, or 66, wherein the HCV is genotype 1b.

71. The use of claims 64, 65, or 66, wherein the patient is treatment-naive.

72. The use of claim 64, wherein the combination further comprises Compound 2, as defined in claim 40, or a pharmaceutically acceptable salt thereof, in the manufacture of a second medicament for the treatment of HCV genotype 1 in the patient..

73. The use of claim 72, wherein the treatment lasts for 8 weeks.

74. The use of claim 72, wherein the treatment lasts for 12 weeks.

75. The use of claims 72, 73, or 74, wherein 150 mg of Compound 1 is adapted for administration once daily together with 100 mg ritonavir, and 25 mg of Compound 4 is adapted for administration once daily, and 400 mg of Compound 2 is adapted for administration twice daily.

76. The use of claims 72, 73, or 74, wherein the pharmaceutically acceptable salt of Compound 2 is the sodium salt.

77. The use of claims 72, 73, or 74, wherein the HCV is genotype 1a.

78. The use of claims 72, 73, or 74, wherein the HCV is genotype 1b.

79. The use of claims 72, 73, or 74, wherein the patient is treatment-naive.

80. Use of Compound 1, as defined in claim 32, or a pharmaceutically acceptable salt thereof, and ritonavir in the manufacture of a first medicament and Compound 4, as defined in claim 32, or a pharmaceutically acceptable salt thereof, in the manufacture of a second medicament, wherein the first and second medicaments are used in combination for the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the treatment does not include the use of either interferon or ribavirin.

81. The use of claim 80, wherin the treatment lasts for 8 weeks.

82. The use of claim 80, wherein the treatment lasts for 12 weeks.

83. The use of claims 80, 81, or 82, wherein the first medicament comprises 150 mg of Compound 1 and is adapted for administration once daily together with 100 mg ritonavir, and the second medicament comprises 25 mg of Compound 4 and is adapted for administration once daily.

84. The use of claims 80, 81, or 82, wherein the HCV is genotype 1a.

85. The use of claims 80, 81, or 82, wherein the HCV is genotype 1b.

86. The use of claims 80, 81, or 82, wherein the patient is treatment-naive.

87. The use of claim 80, further comprising the use of Compound 2, as defined in claim 40, or a pharmaceutically acceptable salt thereof, in the manufacture of a third medicament, wherein the first, second, and third medicaments are used in combination for the treatment of chronic hepatitis C virus infection (HCV) genotype 1 in the patient.

88. The use of claim 87, wherein the treatment lasts for 8 weeks.

89. The use of claim 87, wherein the treatment lasts for 12 weeks.

90. The use of claims 87, 88, or 89, wherein the first medicament comprises 150 mg of Compound 1 and 100 mg ritonavir, and is adapted for administration once daily, and the second medicament comprises 25 mg of Compound 4 and is adapted for administration once daily, and 400 mg of Compound 2 is adapted for administration twice daily.

91. The use of claims 87, 88, or 89, wherein the pharmaceutically acceptable salt of Compound 2 is the sodium salt.

92. The use of claims 87, 88, or 89, wherein the HCV is genotype 1a.

93. The use of claims 87, 88, or 89, wherein the HCV is genotype 1b.

94. The use of claims 87, 88, or 89, wherein the patient is treatment-naive.

95. Use of Compound 1 and Compound 4, both as defined in claim 32, or a pharmacteutically acceptable salt thereof, and ritonavir, in combination with Compound 2, as defined in claim 40, or a pharmaceutically acceptable salt thereof, for the treatment of hepatitis C virus (HCV) genotype 1 in a patient, wherein the Compound 1, or a pharmaceutically acceptable salt thereof and Compound 4, or a pharmacteutically acceptable salt thereof, and ritonavir are co-formulated in a single

composition, and wherein the treatment does not include the use of either interferon or ribavirin.

96. The use of claim 95, wherin the treatment lasts for 8 weeks.

97. The use of claim 95, wherein the treatment lasts for 12 weeks.

98. The use of claims 95, 96, or 97, wherein the pharmaceutically acceptable salt of Compound 2 is the sodium salt.

99. The use of claims 95, 96, or 97, wherein the HCV is genotype 1a.

100. The use of claims 95, 96, or 97, wherein the HCV is genotype 1b.

101. The use of claims 95, 96, or 97, wherein the patient is treatment-naive.